The addition of ibrutinib and lenalidomide to DA-EPOCH-R was hypothesized to inhibit BCR signaling and NF-κB activation, thus improving the outcomes of patients with R/R ABC DLBCL. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.